Rapt Therapeutics (RAPT) Competitors $8.62 +0.18 (+2.13%) Closing price 07/10/2025 04:00 PM EasternExtended Trading$8.62 0.00 (-0.06%) As of 07/10/2025 04:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RAPT vs. OPT, MGTX, TYRA, BCAX, KURA, TSHA, MNMD, ABVX, VALN, and ZVRAShould you be buying Rapt Therapeutics stock or one of its competitors? The main competitors of Rapt Therapeutics include Opthea (OPT), MeiraGTx (MGTX), Tyra Biosciences (TYRA), Bicara Therapeutics (BCAX), Kura Oncology (KURA), Taysha Gene Therapies (TSHA), Mind Medicine (MindMed) (MNMD), Abivax (ABVX), Valneva (VALN), and Zevra Therapeutics (ZVRA). These companies are all part of the "pharmaceutical products" industry. Rapt Therapeutics vs. Its Competitors Opthea MeiraGTx Tyra Biosciences Bicara Therapeutics Kura Oncology Taysha Gene Therapies Mind Medicine (MindMed) Abivax Valneva Zevra Therapeutics Opthea (NASDAQ:OPT) and Rapt Therapeutics (NASDAQ:RAPT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment. Do institutionals and insiders hold more shares of OPT or RAPT? 56.0% of Opthea shares are held by institutional investors. Comparatively, 99.1% of Rapt Therapeutics shares are held by institutional investors. 3.2% of Opthea shares are held by company insiders. Comparatively, 2.4% of Rapt Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has preferable earnings & valuation, OPT or RAPT? Rapt Therapeutics has higher revenue and earnings than Opthea. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOpthea$120K4,373.61-$220.24MN/AN/ARapt Therapeutics$1.53M93.19-$129.87M-$19.20-0.45 Do analysts recommend OPT or RAPT? Opthea presently has a consensus target price of $1.33, suggesting a potential downside of 60.90%. Rapt Therapeutics has a consensus target price of $19.80, suggesting a potential upside of 129.70%. Given Rapt Therapeutics' higher probable upside, analysts clearly believe Rapt Therapeutics is more favorable than Opthea.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Opthea 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.17Rapt Therapeutics 1 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17 Does the media refer more to OPT or RAPT? In the previous week, Rapt Therapeutics had 3 more articles in the media than Opthea. MarketBeat recorded 4 mentions for Rapt Therapeutics and 1 mentions for Opthea. Rapt Therapeutics' average media sentiment score of 0.78 beat Opthea's score of 0.55 indicating that Rapt Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Opthea Positive Rapt Therapeutics Positive Is OPT or RAPT more profitable? Opthea's return on equity of 0.00% beat Rapt Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets OptheaN/A N/A N/A Rapt Therapeutics N/A -81.47%-70.24% Which has more risk & volatility, OPT or RAPT? Opthea has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500. Comparatively, Rapt Therapeutics has a beta of -0.09, meaning that its share price is 109% less volatile than the S&P 500. SummaryRapt Therapeutics beats Opthea on 7 of the 13 factors compared between the two stocks. Get Rapt Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RAPT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RAPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RAPT vs. The Competition Export to ExcelMetricRapt TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$139.57M$2.96B$5.55B$9.03BDividend YieldN/A2.43%5.25%4.04%P/E Ratio-0.4521.1127.2020.14Price / Sales93.19251.53413.1198.19Price / CashN/A42.7337.5058.41Price / Book0.757.748.085.60Net Income-$129.87M-$54.96M$3.16B$248.43M7 Day Performance6.09%9.10%4.70%5.47%1 Month Performance-2.05%5.73%4.50%7.87%1 Year Performance-69.04%2.79%31.01%18.75% Rapt Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RAPTRapt Therapeutics4.4177 of 5 stars$8.62+2.1%$19.80+129.7%-67.9%$139.57M$1.53M-0.4580Analyst ForecastOPTOpthea0.3212 of 5 stars$3.41+7.2%$1.33-60.9%+72.6%$524.83M$120K0.008Gap UpMGTXMeiraGTx4.4444 of 5 stars$6.52-1.4%$24.00+268.1%+108.2%$523.95M$33.28M-2.81300Insider TradeTYRATyra Biosciences1.891 of 5 stars$9.57+5.2%$30.83+222.2%-43.5%$508.07MN/A-5.8720BCAXBicara Therapeutics1.4398 of 5 stars$9.29+6.7%$31.86+242.9%N/A$506.68MN/A0.0032KURAKura Oncology4.5609 of 5 stars$5.77+1.8%$24.50+324.6%-68.7%$499.54M$67.99M-2.75130TSHATaysha Gene Therapies2.7366 of 5 stars$2.31-2.9%$8.00+246.3%+12.8%$495.87M$8.33M-6.79180MNMDMind Medicine (MindMed)3.0059 of 5 stars$6.49-0.9%$25.50+292.9%+14.1%$490.32MN/A-5.0340Positive NewsABVXAbivax2.6182 of 5 stars$7.65+3.4%$31.00+305.2%-37.1%$485.39MN/A0.0061Positive NewsGap UpHigh Trading VolumeVALNValneva1.534 of 5 stars$5.67-2.2%$15.50+173.4%-16.3%$482.46M$183.52M-4.76700ZVRAZevra Therapeutics2.8005 of 5 stars$8.81-2.1%$22.29+153.0%+113.9%$481.73M$23.61M-4.6420News CoverageAnalyst ForecastGap Up Related Companies and Tools Related Companies Opthea Competitors MeiraGTx Competitors Tyra Biosciences Competitors Bicara Therapeutics Competitors Kura Oncology Competitors Taysha Gene Therapies Competitors Mind Medicine (MindMed) Competitors Abivax Competitors Valneva Competitors Zevra Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RAPT) was last updated on 7/11/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rapt Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Rapt Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
